Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
AssigneesDeutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Universitaetsklinikum Heidelberg
InventorsAna Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
Claims7
A method for treating high grade glioma in an individual, comprising administering to an individual having high grade glioma the only active ingredient of an anti-human CD95 ligand (CD95L) antibody or an antigen binding fragment thereof that neutralizes CD95L activity, wherein the only active ingredient is administered in an amount sufficient to reduce glial cell migration and/or invasion.
Dependencies are inferred from the claim text.